Discover 2,427 paid clinical trials in Maryland. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Maryland provides numerous clinical research opportunities for both healthy volunteers and individuals with particular health conditions. Research centers in Baltimore, Rockville, and Annapolis are actively recruiting, giving access to innovative therapies and comprehensive care.
Filter
1
Filter results
Results: 2,427
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
for
Radiographic Axial Spondyloarthritis
Location: Quebec, Trois-Rivieres, Philadelphia PA, Baltimore MD,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18 - 70+
Code: NCT07133633
Phase2, Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer
Location: Hartford CT, Sherbrooke, New York NY, Montreal,
Sponsor: Amgen
Sex: Male
Age: 18+
Code: NCT07213674
Phase3, Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
for
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Location: Boston MA, New Haven CT, Manhasset NY, Rosedale NY,
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18+
Code: NCT07207811
Phase3, Recruiting
Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research
for
Endothelial Dysfunction,
Location: Bethesda MD
Sponsor: National Institutes of Health Clinical Center (CC)
Sex: All
Age: 18 - 70+
Code: NCT03253705
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
for
Chronic Obstructive Pulmonary Disease
Location: New Bedford MA, Quebec, Victoriaville, Trois-Rivieres,
Sponsor: Sanofi
Sex: All
Age: 40 - 70+
Code: NCT07190222
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Intent of Surgery for IPMN
for
Intraductal Papillary Mucinous Neoplasm
Location: Boston MA, New York NY, Baltimore MD, Durham NC,
Sponsor: NYU Langone Health
Sex: All
Age: 18+
Code: NCT07216521
Recruiting
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Location: Bethesda MD, Charlottesville VA, Pittsburgh PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06965114
Phase1, Phase2, Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Location: Baltimore MD, Boca Raton FL, Midland MI, Richmond IN,
Sponsor: Abcentra
Sex: All
Age: 18+
Code: NCT06927739
Phase2, Recruiting
A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
Sex: All
Age: 18+
Code: NCT07096271
Recruiting
Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders
for
Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa),
Location: Bethesda MD, Indianapolis IN
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sex: All
Age: 0 - 70+
Code: NCT05656365
Recruiting
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)